These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 18080406)

  • 1. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
    Technol Eval Cent Assess Program Exec Summ; 2007 Nov; 22(6):1-3. PubMed ID: 18080406
    [No Abstract]   [Full Text] [Related]  

  • 2. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
    Technol Eval Cent Assess Program Exec Summ; 2011 Mar; 25(6):1-5. PubMed ID: 21638942
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
    Gridelli C
    Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.
    Kotsakis A; Georgoulias V
    Expert Opin Pharmacother; 2010 Oct; 11(14):2363-89. PubMed ID: 20586711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities.
    da Cunha Santos G; Saieg MA; Geddie W; Leighl N
    Cancer Cytopathol; 2011 Apr; 119(2):80-91. PubMed ID: 21400669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations.
    Yuan S; Yu SL; Chen HY; Hsu YC; Su KY; Chen HW; Chen CY; Yu CJ; Shih JY; Chang YL; Cheng CL; Hsu CP; Hsia JY; Lin CY; Wu G; Liu CH; Wang CD; Yang KC; Chen YW; Lai YL; Hsu CC; Lin TC; Yang TY; Chen KC; Hsu KH; Chen JJ; Chang GC; Li KC; Yang PC
    J Clin Oncol; 2011 Sep; 29(25):3435-42. PubMed ID: 21810691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T; Liu G; Tsao MS
    Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
    Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
    Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
    Wong KK
    Lung Cancer; 2008 Jun; 60 Suppl 2():S10-8. PubMed ID: 18513579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients.
    Murray S; Timotheadou E; Linardou H; Vrettou AV; Kostopoulos I; Skrickova J; Papakostantinou C; Christodoulou C; Pectasides D; Samantas E; Papakostas P; Skarlos DV; Kosmidis P; Fountzilas G
    Lung Cancer; 2006 May; 52(2):225-33. PubMed ID: 16567021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First case of A859T epidermal growth factor receptor mutation responding to erlotinib.
    Le Maignan L; Mirebeau-Prunier D; Vervueren L; Jeanfaivre T; Urban T; Hureaux J
    J Thorac Oncol; 2011 Mar; 6(3):639-40. PubMed ID: 21317745
    [No Abstract]   [Full Text] [Related]  

  • 13. Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making.
    Gandara DR; Lara PN; Mack P; Scagliotti G
    Clin Lung Cancer; 2009 May; 10(3):148-50. PubMed ID: 19443333
    [No Abstract]   [Full Text] [Related]  

  • 14. Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation.
    van Noesel J; van der Ven WH; van Os TA; Kunst PW; Weegenaar J; Reinten RJ; Kancha RK; Duyster J; van Noesel CJ
    J Clin Oncol; 2013 Apr; 31(10):e161-4. PubMed ID: 23358982
    [No Abstract]   [Full Text] [Related]  

  • 15. Lung cancer: intragenic ERBB2 kinase mutations in tumours.
    Stephens P; Hunter C; Bignell G; Edkins S; Davies H; Teague J; Stevens C; O'Meara S; Smith R; Parker A; Barthorpe A; Blow M; Brackenbury L; Butler A; Clarke O; Cole J; Dicks E; Dike A; Drozd A; Edwards K; Forbes S; Foster R; Gray K; Greenman C; Halliday K; Hills K; Kosmidou V; Lugg R; Menzies A; Perry J; Petty R; Raine K; Ratford L; Shepherd R; Small A; Stephens Y; Tofts C; Varian J; West S; Widaa S; Yates A; Brasseur F; Cooper CS; Flanagan AM; Knowles M; Leung SY; Louis DN; Looijenga LH; Malkowicz B; Pierotti MA; Teh B; Chenevix-Trench G; Weber BL; Yuen ST; Harris G; Goldstraw P; Nicholson AG; Futreal PA; Wooster R; Stratton MR
    Nature; 2004 Sep; 431(7008):525-6. PubMed ID: 15457249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experience on epidermal growth factor receptor gene mutation analysis in non-small cell lung cancer].
    Zhang J; Gao J; Liang ZY; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):712-4. PubMed ID: 22321558
    [No Abstract]   [Full Text] [Related]  

  • 17. [Comparison of two different methods for EGFR gene mutation detection in non-small cell lung cancer].
    Dong Z; Sun Y; Lu Y; Tang C; Xu Y; Liu Y; Zhu G; Liu X
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):116-9. PubMed ID: 24742573
    [No Abstract]   [Full Text] [Related]  

  • 18. Unlocking the biological clues of lung cancer.
    Hanna N
    J Thorac Oncol; 2008 Aug; 3(8):809-10. PubMed ID: 18670296
    [No Abstract]   [Full Text] [Related]  

  • 19. A sequential method of epidermal growth factor receptor mutation detection reduces false negatives: a new case with doublet mutations of L833V and H835L in China.
    Zhuang Y; Xu J; Ma H; Zhu W; Guo L; Kang S; Guo F
    Clin Lung Cancer; 2013 May; 14(3):295-300. PubMed ID: 23313172
    [No Abstract]   [Full Text] [Related]  

  • 20. Rapid detection of hotspot mutations in epidermal growth factor receptor by polymerase chain reaction facilitates the management of non-small cell lung cancer.
    Hung KS; Lee CN; Liu HE
    J Thorac Oncol; 2008 Oct; 3(10):1202-3. PubMed ID: 18827621
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.